A Clinical Trial Assessing the Impact of Inhaled Insulin on Glucose Disposition

Phase 3TerminatedNCT00287066

Pfizer22 enrolled

Overview

To assess the impact of inhalation of insulin on glucose disposition in patients with type 1 diabetes

The study was terminated on Oct. 28, 2007. The protocol was undergoing implementation and methodological issues with major revisions that qualified this trial as a new trial. Pfizer decided to cancel new trials because of the decision to withdraw Exubera due to lack of market performance and not for safety reasons.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Diabetes Mellitus

Interventions

Inhaled Human InsulinDRUG

Regular Human InsulinDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 50 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Diabetes mellitus Type 1 Exclusion Criteria: * Asthma, COPD * Smoking

Locations (1)

Pfizer Investigational Site

Pittsburgh, Pennsylvania, United States

Outcomes

Primary Outcomes

18F-labeled glucose uptake in muscle

Secondary Outcomes

Glucose turnover overnight Insulin pharmacokinetics

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.